Pfizer executive William Ringo to retire
NEW YORK A Pfizer executive credited with diversifying the company’s portfolio and helping create a joint venture with GlaxoSmithKline focused on HIV will retire, Pfizer announced Friday.
William Ringo plans to step down as SVP worldwide business development, strategy and innovation. Kristin Peck, SVP worldwide strategy and innovation, will replace him.
“It has been a real pleasure to be part of Pfizer’s executive leadership team,” Ringo said in a statement. “Based on my four decades of experience in the industry, I truly believe the future of Pfizer is extremely bright, as our colleagues provide quality medicines to patients around the world.”
Ringo began working for Pfizer in April 2008 after working for Eli Lilly for 28 years. His work at Pfizer included helping to create the HIV-focused joint venture with GSK, ViiV Healthcare, which combines the two companies’ portfolios of HIV drugs.
Kerr Drug honored for MTM services
RALEIGH, N.C. Thousands of patient interventions by Kerr Drug pharmacists have earned the chain recognition from a leading pharmaceutical health provider as the nation’s top provider of pharmacy-based medication therapy management.
It’s the third year in a row Kerr has won the honor, bestowed by Outcomes Pharmaceutical Health Care, a national MTM provider network. In bestowing the award, Outcomes noted that Kerr pharmacists served nearly 10,000 MTM-eligible patients in 2008, saving more than $2 million in estimated costs.
“Over the past year, Kerr Drug has remained a front-runner in the provision of MTM services and has clearly demonstrated the value pharmacists deliver to the health care system,” said Outcomes VP Brand Newland.
Outcomes also named the Kerr store in Moncks Corner, S.C., as the top individual pharmacy for 2008 in its eighth region, an operating area that represents Georgia and South Carolina.
New drug application review for Exenatide extended
INDIANAPOLIS A diabetes drug developed by Amylin, Eli Lilly and Alkermes will be reviewed by the Food and Drug Administration March 12.
The revised action date of Exenatide once weekly is the result of the FDA’s decision to allow five additional days for its review of pending regulatory applications following the agency’s recent five-day weather-related closure.
Exenatide once weekly is an investigational, extended-release medication for Type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. The NDA for exenatide once weekly was submitted in May 2009 and accepted by the FDA in July 2009.